- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04865341
Mobile-health (mHealth) Intervention to Support HIV Self-testing and PrEP Uptake Among Young Men Who Have Sex With Men
April 28, 2026 updated by: Steven A John, Medical College of Wisconsin
Optimizing an IMB-guided Intervention to Support HIV Self-testing and PrEP Uptake Among YMSM: A Pilot Randomized Controlled Trial
The proposed study will involve adolescent (17-24 years old) men who have sex with men (described as YMSM hereafter) who meet eligibility criteria to participate.
Prospective study candidates will receive a copy of the IRB-approved informed consent forms and, if they choose to participate, will provide consent before enrollment into this study.
Involvement of human subjects is detailed in the Research Strategy portion of this proposal, Recruitment and Retention Plan, and Protection of Human Subjects sections.
Briefly, investigators will develop and pilot a randomized controlled trial (RCT) to support HIV self-testing (HIVST) and pre-exposure prophylaxis (PrEP) uptake.
Intervention content will be focused on constructs of the Information-Motivation-Behavioral Skills (IMB) model.
To reduce cost and increase feasibility, investigators plan to incorporate previously developed content as much as possible-investigators see integration of this content as a major strength.
Investigators will include content about HIV testing and PrEP and other resources including the geo-targeted directories to find clinic settings that offer HIV testing and PrEP, all of which are publicly available.
Investigators believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change.
Investigators foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the intervention.
Intervention content was developed on feedback from focus groups, survey results, youth advisory board feedback, and usability testing.
Primary endpoints of this study include HIVST and PrEP uptake, including stage of change towards HIVST and PrEP uptake.
Secondary outcomes include changes in IMB model indicators (e.g., HIV prevention knowledge).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The research activity designated as a clinical trial is our pilot RCT where investigators will then enroll 120 YMSM and randomly assign individuals to one of two experimental groups: (1) information-only (I), and (2) information + motivation + behavioral skills (IMB).
Randomization will be blinded using Qualtrics, and randomization will occur in a ratio of 1:1 between the two groups.
Individuals assigned to group 1 will receive attention-matched information-only content about HIVST and PrEP related information.
Intervention content will be based upon the formative research.
After completion of the baseline survey, randomization, and intervention, participants will be followed for a period of three months.
Individuals will be surveyed at 1- and 3-months post intervention to assess our primary endpoints of HIVST and PrEP uptake.
Preliminary impact will be assessed using within- and between-subjects analyses.
First, investigators will test the performance of randomization by chi-squared comparisons and ANOVAs for categorical and continuous variables, respectively.
Second, investigators will test for differential attrition by treatment group at 1- and 3-month follow-up assessments.
Third, investigators will assess post-intervention HIV testing and PrEP uptake using factorial logistic regressions to determine between-group differences, adjusting for any breakdowns in randomization or differential attrition.
Fourth, investigators will test for changes in stage of change indicators by randomized group, time, and group*time interaction, with similar adjustment procedures, using GEE; this analysis will help us determine a trend towards HIVST or PrEP uptake were investigators to extend the length of follow-up.
Power: Our study has 80% power to detect a ½ stage average difference (d = 0.68; α = 0.05) on the PrEP cascade comparing the three experimental groups combined to the information-only control assuming 80% retention.
As the purpose of this study is to pilot the RCT, investigators have not powered this study to determine differences between the experimental group compared to the control group (which is planned for the full RCT in a future R01).
Finally, investigators will conduct within-subjects tests comparing baseline and follow-up IMB construct scale scores stratified by group as an evaluation of internal validity (i.e., did the interventions have an effect on the targeted constructs?).
Study Type
Interventional
Enrollment (Actual)
118
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years to 24 years (Child, Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 17-24 years old;
- Individuals who self-identify as male (including transgender men) and report any male sexual partners in the past 6 months;
- Resident of the US based on home address;
- HIV-negative or unknown status based on self-report; and
Self-reported risk for HIV (based on CDC criteria for PrEP use) defined as reporting any of the following in the past six months:
- Bacterial STI
- Condomless anal sex (CAS) with a casual male sexual partner
- CAS with an HIV-positive or unknown status main partner
- CAS with an HIV-negative main partner who reports CAS with other male partners.
Exclusion Criteria:
- Current PrEP use;
- Unstable, serious psychiatric symptoms;
- Currently suicidal/homicidal; and
- Evidence of gross cognitive impairment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: IMB
Individuals randomized to this arm will receive a behavioral intervention based on the Information-Motivation-Behavior (IMB) model designed to increase HIV self-testing, among other protective behaviors.
|
Intervention content will be focused on the Information-Motivation-Behavioral Skills (IMB) model.
We plan to incorporate previously developed content as much as possible and will include content about HIV testing and PrEP and other resources.
We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change.
We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the intervention.
|
|
Other: Information-Only Control
Attention-matched comparison condition (information-only)
|
Intervention content will be focused on the information construct of the Information-Motivation-Behavioral Skills (IMB) model.
We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources.
We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change.
We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Self-reported Self-administration of HIV Testing
Time Frame: 3 months
|
Self-reported self-administration of HIV testing within the past 3 months (i.e., since baseline assessment).
|
3 months
|
|
Number of Participants With Self-reported PrEP Uptake
Time Frame: 3 months
|
Self-reported PrEP uptake
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Steven A John, MPH, PhD, Medical College of Wisconsin
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- John SA, Lopez-Rios J, Starks TJ, Rendina HJ, Grov C. Willingness to Distribute HIV Self-Testing Kits to Recent Sex Partners Among HIV-Negative Gay and Bisexual Men and an Examination of Free-Response Data from Young Men Participating in the Nationwide Cohort. Arch Sex Behav. 2020 Aug;49(6):2081-2089. doi: 10.1007/s10508-020-01752-5. Epub 2020 Jun 3.
- John SA, Walsh JL, Quinn KG, Cho YI, Weinhardt LS. Testing the Interpersonal-Behavior model to explain intentions to use patient-delivered partner therapy. PLoS One. 2020 May 20;15(5):e0233348. doi: 10.1371/journal.pone.0233348. eCollection 2020.
- John SA, Quinn KG, Pleuhs B, Walsh JL, Petroll AE. HIV Post-Exposure Prophylaxis (PEP) Awareness and Non-Occupational PEP (nPEP) Prescribing History Among U.S. Healthcare Providers. AIDS Behav. 2020 Nov;24(11):3124-3131. doi: 10.1007/s10461-020-02866-6.
- Quinn KG, Zarwell M, John SA, Christenson E, Walsh JL. Perceptions of PrEP Use Within Primary Relationships Among Young Black Gay, Bisexual, and Other Men Who Have Sex with Men. Arch Sex Behav. 2020 Aug;49(6):2117-2128. doi: 10.1007/s10508-020-01683-1. Epub 2020 Apr 2.
- Pleuhs B, Quinn KG, Walsh JL, Petroll AE, John SA. Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review. AIDS Patient Care STDS. 2020 Mar;34(3):111-123. doi: 10.1089/apc.2019.0189. Epub 2020 Feb 28.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 21, 2024
Primary Completion (Actual)
August 31, 2024
Study Completion (Actual)
August 31, 2024
Study Registration Dates
First Submitted
April 26, 2021
First Submitted That Met QC Criteria
April 26, 2021
First Posted (Actual)
April 29, 2021
Study Record Updates
Last Update Posted (Actual)
May 1, 2026
Last Update Submitted That Met QC Criteria
April 28, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Urogenital Diseases
- Genital Diseases
- Immune System Diseases
- Infections
- RNA Virus Infections
- Virus Diseases
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- PRO34897
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Datasets will be deposited in the NIMH Data Archive (NDA)
IPD Sharing Time Frame
Approximately available by December 31, 2027 aligned with results publishing; available indefinitely.
IPD Sharing Access Criteria
Data will be findable for the research community through the NIH Data Archive (NDA) Collection
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsCompletedHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
Oswaldo Cruz FoundationRecruitingContact With or Exposure to Human Immunodeficiency VirusBrazil
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
bioLytical LaboratoriesCompletedHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II InfectionCanada
-
bioLytical LaboratoriesCompletedHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II InfectionUnited States
-
Immuno Cure Holding (HK) LimitedThe University of Hong Kong; Immuno Cure 1 LimitedRecruitingHuman Immunodeficiency Virus | Human Immunodeficiency Virus I InfectionHong Kong
Clinical Trials on Information-Only Control
-
Vanderbilt UniversityNational Institutes of Health (NIH)CompletedHelp-Seeking Behavior
-
University of PittsburghCompletedStroke | Dementia | Heart DiseaseUnited States
-
Stony Brook UniversityNot yet recruitingDepression | Relational Problems
-
Northwestern UniversityNational Institute of Mental Health (NIMH); National Institutes of Health (NIH)Recruiting
-
Northwestern UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedQuality of Life | Inflammation | Sleep Disturbance | Bereavement | SpousesUnited States
-
Duke UniversityStanford University; University of North Carolina, Chapel Hill; World BankCompleted
-
University of PittsburghNational Institute on Aging (NIA)CompletedNocturnal Enuresis | Nocturia | Sleep Fragmentation | Poor Quality SleepUnited States
-
Wayne State UniversityUniversity of Southern CaliforniaCompleted
-
Ohio State UniversityUniversity of South Florida; American Cancer Society, Inc.Completed
-
Icahn School of Medicine at Mount SinaiNational Cancer Institute (NCI)Completed